Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 20 Publications

8 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    a Immunofluorescence of HA–cGAS in transfected HCA2-TERT cells exposed to etoposide (100 μg/ml) for 4 h. b, Immunoblot of endogenous cGAS in the cytoplasmic and nuclear fractions of HCA2-TERT cells treated with etoposide for the indicated times

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

  • j, Immunoblot of cell lysates of PC-9 cells that stably express HA–cGAS, transfected with either shCtrl or shBLK after etoposide (100 μg ml−1) treatment for 4 h.

    Nature, 2018, 563(7729):131-136. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NWWzcG9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMUNihKnDueLCiUCuNFEh|ryP MoLzNlU6PjB{OEK=
KellyCis83 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMUdihKnDueLCiUCuNFIh|ryP MXGyOVk3ODJ6Mh?=
SK-N-AS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m1dGlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= NInhelUzPTl4MEK4Ni=>
U87 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfyUmgxNTVyIN88US=> MUi0PEBp NU\BSJN3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDzbYxq[mmwaX6= M2X4dlI2PzVyMkez
HCT116 M3z0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHuNE42NTJwNTFOwG0> M{jsflQ5yqCqwrC= NGTVU5NKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= MUWyOVc1Pjd4Mx?=
HT-29 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUn1[oJbOC53LUKuOUDPxE1? NYXMPVBtPDkEoHlCpC=> NFSzNoxKSzVyPUeuNuKhyrIEoEGuNFTDqM7:TR?= M2\MSlI2PzR4N{[z
Caco2 M{Twe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjENE42NTJwNTFOwG0> NWnyRlVQPDkEoHlCpC=> MlvXTWM2OD15LkK2xsDDucLiMT62POKh|ryP NH;BUoMzPTd2Nke2Ny=>
COLO 205 NIL6OJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDVNE42NTJwNTFOwG0> NGPlTGg1QMLiaNMg Mk\hTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP MnnuNlU4PDZ5NkO=
SW480 NWfDOXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KyRVAvPS1{LkWg{txO MVG0POKhcMLi MUPJR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? M4rQbVI2PzR4N{[z
HEK293T NXzFSmFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzDUFhSOS13IN88US=> M3L2UVQ5yqCqwrC= NIfnRXhKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= MWGyOVc1Pjd4Mx?=
Hep3B  MY\GeY5kfGmxbjDBd5NigQ>? NGfxfpEyOCEQvF2= MmK5OFjDqGkEoB?= NVrFRVNOemWmdXPld{B1cGViZX7oZY5kcW6pIHXm[oVkfCCxZjDCUXAuPg>? NIfhcJczPTZ|M{W2OC=>
Hep3B  Mm\PSpVv[3Srb36gRZN{[Xl? NWK5c5ZpOC5zLUGwJO69VQ>? M1[weVI1KGh? MWrzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? M2PqdVI2PjN|NU[0
HEK293 NGXTWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7KPGdKSzVyPUeuNVTDqMLzwrCwMlM3yqEQvF2= M2jLOVI2PjB|MUKy
DU145 M{DlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LNU2lEPTB;Mj6yPOKhyrIEoECuNFTDqM7:TR?= NF[4NIozPTZyM{GyNi=>
HCT15 NH\UXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jJ[mlEPTB;MD64NeKhyrIEoECuNFHDqM7:TR?= NFfYPGgzPTZyM{GyNi=>
T47D NEfySoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnIOXBuUUN3ME2zMlE5yqEEsdMgNE4yOcLizszN NGXkU|czPTZyM{GyNi=>
SMMC-7721 MWHGeY5kfGmxbjDBd5NigQ>? M1u5flQxKM7:TR?= NFHUO5U1QCCq NIfSNnRFVVOR M2j6Uolv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v M3Ps[FI2PTR2M{[x
MDA-MB-231 NHPxNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlflO|LDqGh? NG\DfmhKSzVyPUKxMlLDqMLzwrC0MlLDqM7:TR?= NWr3e2tvOjV2OE[yNVk>
Jurkat M33DXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jwbVczyqCq NE\xZ5FKSzVyPUGuNuKhyrIEoEGuOeKh|ryP M3zuTFI2PDh4MkG5
HeLa MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTY[WxvPzMEoHi= M4Lm[mlEPTB;Mz65xsDDucLiMj6zxsDPxE1? MXSyOVQ5PjJzOR?=
MCF7  NGrZOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLxOU0yODBizszN Mk\DO{Bl NH30U41qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2n2NFI2PDd{NkG5
K562 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUS3NuKhcA>? MlPETWM2OD1yLkK5xsDPxE1? MY[yOVI5OjZ3Mx?=
K/VP.5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjvVo04OsLiaB?= NIj6dXRKSzVyPUSuPeKh|ryP NG[4U5czPTJ6Mk[1Ny=>
SH-EP  NHjpdpJHfW6ldHnvckBCe3OjeR?= NGmweFkzOMLizsznM41t NIfMeHozPMLiaB?= MY\pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS MWeyOVI3OTl6MR?=
SCC25 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnDNlTDqGh? NH:2[HhKSzVyPUSzMlPDqMLzwrCxMlEzyqEQvF2= MVuyOVIzODd{OR?=
CAL27 M{PIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGyOOKhcA>? NYXPXW5wUUN3ME21Nk4yyqEEsdMgNU4xQcLizszN M1jKTFI2OjJyN{K5
FaDu NVTGN2tvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LMR|I1yqCq NGDlWXFKSzVyPUK1Mlg6yqEEsdMgNU4yO8LizszN MnzqNlUzOjB5Mkm=
SCC25 NITrVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPwSFN5PDkEoHi= NUnaNHVZUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> M{fzcFI2OjJyN{K5
FaDu NYS0bI9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fLTVQ5yqCq M4nBdmlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= M4K1SlI2OjJyN{K5
SCC25 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrLNVRvPzMEoHi= M{naTGlEPTB;OD60NeKhyrIEoEGuNVHDqM7:TR?= MViyOVIzODd{OR?=
CAL27 NUDDfIxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELxSHc4OsLiaB?= MYHJR|UxRTRwMkhCpOKyyqBzLkG0xsDPxE1? NHnwRoozPTJ{MEeyPS=>
FaDu M3nxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYK3NuKhcA>? MYLJR|UxRTVwMENCpOKyyqBzLkG1xsDPxE1? NWHGO4d2OjV{MkC3Nlk>
MCF-7 NWnnfotFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fCUFQ5yqCqwrC= NX7SbI41TE2VTx?= MVnJR|UxRTdwMtMgxtHDqDBwONMg{txO Ml:xNlUzOTZ|N{i=
T-47D NXHvZ2dYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33hVVQ5yqCqwrC= M{XqZWROW09? MkHGTWM2OD15LkhCpOKyyqByLkhCpO69VQ>? NYL2[IN7OjV{MU[zO|g>
MDA-MB-231 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn4UWU1QMLiaNMg MWjEUXNQ MYTJR|UxRTF{LklCpOKyyqBzLkFCpO69VQ>? Mn;1NlUzOTZ|N{i=
DU145 M{jQWGFxd3C2b4Ppd{BCe3OjeR?= M4ftZlExNTFyMDFOwG0> NHPMVoo5KGh? MXTEUXNQ NIfCcXpqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= NEPL[FkzPTF2OU[4NS=>
DU145 stem-like M4DnXmFxd3C2b4Ppd{BCe3OjeR?= NWToOHFwOTBvMUCwJO69VQ>? MXK4JIg> MYjEUXNQ NEfuZY5qdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4jBNFI2OTR7Nkix
DU145 NGrJSo5HfW6ldHnvckBCe3OjeR?= M3TmcVExNTFyMDFOwG0> MYmyJIg> MV3EUXNQ NU\iR|F{cW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGjsdIUzPTF2OU[4NS=>
DU145 stem-like NX\WZXVSTnWwY4Tpc44hSXO|YYm= NWHxNJhkOTBvMUCwJO69VQ>? NWXBSVBUOiCq NUjxOFFmTE2VTx?= M4foZYlv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWLhVpFsOjVzNEm2PFE>
UW228-3 NUGzcFZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiwMlAyNTNyMDFOwG0> NFzGNpk1QCCq MmjVSG1UVw>? MmDYTWM2OD1yLkm5xsDPxE1? NGH1dlEzPTFzOUG4OS=>
MKL-1  NFTsVoFHfW6ldHnvckBCe3OjeR?= Mk\2NVAuOTByMDDuUS=> M4LZc|Qh\A>? MV7pcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? NUPYPWFqOjVzMU[3OVQ>
MCF7 EV MWnGeY5kfGmxbjDBd5NigQ>? NHLpW4YyOC1zMECg{txO MW[y5qCKcA>? MmLjbY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> MkjKNlUxQDh{MEO=
MCF 7BMI1 NHuyRphHfW6ldHnvckBCe3OjeR?= M36zW|ExNTFyMDFOwG0> NIL5fpUz6oDLaB?= MkX0bY5lfWOnczDwdo9lfWO2aX;uJI9nyqEQs1iyRXg> M1n5XVI2ODh6MkCz
HepG2 M2fTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m0S2ROW00EoB?= M1\qb2lEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= M3jHdFI2ODd6M{Gx
HT1080 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTWTo1mOS1zMECg{txO M2nDd|QwOjRxNEigbC=> NYPqV4t3TE2VT9Mg MlLWbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w NUfKd|VlOjVyN{iwOlQ>
HT1080 NVvKfXNSTnWwY4Tpc44hSXO|YYm= MVGwMlAxODFvMUCwJO69VQ>? MUixMVI1KGh? NGfKSZlFVVORwrC= MofvbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NVXJflFSOjVyN{iwOlQ>
HT1080 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH33TY4xNjByMEGtNVAxKM7:TR?= MoHWNlQhcA>? MoHRSG1UV8Li NWHkZVh3[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> Ml\xNlUxPzhyNkS=
HD-MY-Z NYXkU3h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHSXIUzPC92OD:3NkBp MUTJR|Ux97zgMUCwJO69VQ>? NIjpb2szPTB2OEKzOi=>
DOHH-2 NIXGbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HKSFI1KGh? NHqxeFVKSzVy78{eNVAxKM7:TR?= NGHZfYkzPTB2OEKzOi=>
DOHH-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj0c5ZOPDhiaB?= NYq5UlZKUUN3ME2xPU46yqEQvF2= MUOyOVA1QDJ|Nh?=
DOHH-2 NWq0Vo91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\SbZRtPzJiaB?= NGTlNWNKSzVyPUZCpO69VQ>? MnHaNlUxPDh{M{[=
REH M36xXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTP[FNUPzJiaB?= NHLmWlVKSzVyPUCuNFE2yqEQvF2= MX2yOVA1QDJ|Nh?=
HH M17QWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFiwfXczPCCq NGL6S4NKSzVyPUGwOE44yqEQvF2= MVWyOVA1QDJ|Nh?=
HH NUTGdWxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYG0PEBp MW\JR|UxRTR6LkdCpO69VQ>? Ml;3NlUxPDh{M{[=
HH NFTQO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\DSlczKGh? NE[1XFFKSzVyPUG0MlfDqM7:TR?= MmXiNlUxPDh{M{[=
HuT-78 NUTp[pZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOyOEBp NF3sV5FKSzVyPUmuN:Kh|ryP MXGyOVA1QDJ|Nh?=
HuT-78 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPM[lRDPDhiaB?= NHXaU5JKSzVyPUSuN:Kh|ryP NWCzbIF{OjVyNEiyN|Y>
HuT-78 NH\tU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T2d|czKGh? NV7nWHA3UUN3ME20MlLDqM7:TR?= M37DdVI2ODR6MkO2
OPM-2 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqyOEBp MlfZTWM2OD1{ND6xxsDPxE1? MoLHNlUxPDh{M{[=
OPM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;lNFQ5KGh? NFLoSoJKSzVyPUVCpO69VQ>? NGm5WZAzPTB2OEKzOi=>
OPM-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLVOJo4OiCq NVuyXZcxUUN3ME2xMlPDqM7:TR?= Mm\xNlUxPDh{M{[=
RPMI-8226 M{focGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXeyOEBp NUf3bIdUUUN3ME2xNFYvPsLizszN NHfk[JIzPTB2OEKzOi=>
RPMI-8226 NUD0VIhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7POFghcA>? NH7WeFRKSzVyPUmxMlHDqM7:TR?= MnrRNlUxPDh{M{[=
RPMI-8226 NG\hWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DTc|czKGh? MX3JR|UxRTF2LkpCpO69VQ>? NWLJUVc6OjVyNEiyN|Y>
U-266 NH;JZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDhb4wzPCCq MnLnTWM2OD16Nj6yxsDPxE1? MoriNlUxPDh{M{[=
U-266 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvWOFghcA>? MoXiTWM2OD14OD60xsDPxE1? MUOyOVA1QDJ|Nh?=
U-266 NECyW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nV[lczKGh? NGi4[pNKSzVyPUK3MlTDqM7:TR?= M3:3dVI2ODR6MkO2
Kelly M1T0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrxWJJyOC1zMDFOwG0> NWT4[Y5sPzMEoHi= MlnqTWM2OD1zLkWxPOKh|ryP NELtT4gzPTByOEmwNC=>
SH-SY5Y  M3zQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XPTFAuOTBizszN NFLJeXc4OsLiaB?= MkjUTWM2OD1yLke1OOKh|ryPwrC= NVq5XWE6OjVyMEi5NFA>
SK-N-AS NVnKUnp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4GzUlAuOTBizszN MVO3NuKhcA>? M33DNmlEPTB;MT63NVLDqM7:TdMg MXOyOVAxQDlyMB?=
SK-N-DZ NV\BbIprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL4NE0yOCEQvF2= MmW2O|LDqGh? MVvJR|UxRTVwNEi1xsDPxE1? M2jpd|I2ODB6OUCw
HepG2 M1fVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTLeVJnPDkEoHi= NHfnUlVFVVORwrC= MULJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP M3vjTVI1QTl4MUO2
A549 NX[0dVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHuzeVI1QMLiaB?= M4D2TmROW00EoB?= MYTJR|UxRTJ2MT65xsDDucLiM{GuNlPDqM7:TR?= MkPJNlQ6QTZzM{[=
MCF7 M{\iTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLuW4s1QMLiaB?= NVHJc3E4TE2VT9Mg MYjJR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= NF3FN4wzPDl7NkGzOi=>
HL-60  NEfCN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS4O|LDqGh? MlPITWM2OD1yLkGy5qCG|ryP MYiyOFk6OzBzNB?=
HL-60[R] MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1roWFczyqCq Ml\5TWM2OD1|LkGy5qCG|ryP MkD2NlQ6QTNyMUS=
MCF-7 M{H2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTXfWp2T0l3ME2wMlI2KMLzIECuNUDPxE1? NXnOcpIzOjR7NUO4NlE>
HeLa MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XlPGdKPTB;MD62OEDDuSByLkSg{txO M1T1d|I1QTV|OEKx
MO59K  M3vKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIraeVU4KGR? MWfJR|UxRTBwMUhihKXPxE1? MUSyOFk2OzV4MR?=
MO59J MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HrVlch\A>? Mne2TWM2OD1yLkJihKXPxE1? NGPLW3kzPDl3M{W2NS=>
ME 180 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\aRVQ5yqCqwrC= M2LvU2lEPTB;OD65xsDDucLiMD6z5qCG|ryP NV65R3R5OjR7NUOwNlc>
MCF-7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:0POKhcMLi MojTTWM2OD1{Mz65JOKyKDBwM,MAie69VQ>? NH:2c|gzPDl3M{CyOy=>
HeLa MkPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILGZmk1QMLiaNMg MlTtTWM2OD12LkexJOKyKDFwNPMAie69VQ>? MlTNNlQ6PTNyMke=
MDA-MB-453 Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW4OFjDqGkEoB?= NXqyPYdwUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= M1zxUlI1QTV|MEK3
PC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWS0POKhcMLi NFWyPJZKSzVyPUG0MlQhyrFiMz6yN-KBjc7:TR?= M2HiR|I1QTV|MEK3
HT-29 Ml23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjyeG5iPDkEoHlCpC=> M1P3emlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= NYjxenAyOjR7NUOwNlc>
BGC-823 M{LGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXmyVGYzPDkEoHlCpC=> MWDJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? M{foUVI1Pzl|OEe3
HeLa MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT3eWw1QMLiaNMg NX;QPI06UUN3ME2yNFkvQTBiwsGgNVMvPDJi4pEF{txO Mo\HNlQ4QTN6N{e=
A549 NV3weIV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTSOFjDqGkEoB?= MWHJR|UxRTF|OT61OEDDuSB5LkC15qCG|ryP MVeyOFc6Ozh5Nx?=
HK-2 NYHYWVdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:0POKhcMLi M135OmlEPTB;OT6xO{DDuSBzLkW45qCG|ryP Mn7jNlQ4QTN6N{e=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]


Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56


CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03349346 Withdrawn Diffuse Large B-Cell Lymphoma|Mediastinal B-cell Lymphoma Gilead Sciences June 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1
NCT03864419 Not yet recruiting Burkitt Lymphoma|KSHV-associated Multicentric Castleman Disease|Diffuse Large B-Cell Lymphoma Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI) May 4 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. ; 2.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products0

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID